Avidity biosciences enrolls patients in the marina™ open-label extension study

Adults with myotonic dystrophy type 1 (dm1) in the aoc 1001 phase 1/2 marina™ clinical trial can receive continuity of care as part of marina-ole™ preliminary assessment of safety, tolerability and key biomarkers from phase 1/2 marina trial on track for q4 2022 san diego , aug. 2, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that it has commenced enrolling patients from the phase 1/2 marina™ study into a phase 2 open-label extension study (marina-ole™) of aoc 1001 in adults with myotonic dystrophy type 1 (dm1). all patients enrolled in the randomized, placebo-controlled marina™ clinical trial with aoc 1001 are eligible to enroll in marina-ole.
RNA Ratings Summary
RNA Quant Ranking